Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
J Immunother Cancer
; 7(1): 70, 2019 03 12.
Article
in En
| MEDLINE
| ID: mdl-30871628
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HLA-B Antigens
/
HLA-C Antigens
/
Lymphoma, Follicular
/
Receptors, KIR2DL2
/
Receptors, KIR3DL1
/
Rituximab
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
J Immunother Cancer
Year:
2019
Document type:
Article